Antimicrobial resistance of Helicobacter pylori in an eastern German region.

Autor: Hofreuter D; Department of Biological Safety, German Federal Institute for Risk Assessment, Berlin, Germany.; Brandenburg Medical School, Institute of Laboratory Medicine, Brandenburg Hospital, Brandenburg, Germany., Behrendt J; Practice for Gastroenterology, Brandenburg, Germany., Franz A; Practice for Gastroenterology, Bad Belzig, Germany., Meyer J; Practice for Gastroenterology, Berlin, Germany., Jansen A; Brandenburg Medical School, Institute of Laboratory Medicine, Brandenburg Hospital, Brandenburg, Germany., Bluemel B; Faculty of Medicine, Institute of Medical Microbiology and Hygiene, Medical Center-University of Freiburg, Freiburg, Germany., Eisele B; Faculty of Medicine, Institute of Medical Microbiology and Hygiene, Medical Center-University of Freiburg, Freiburg, Germany., Koken M; Brandenburg Medical School, Institute of Laboratory Medicine, Brandenburg Hospital, Brandenburg, Germany., Glocker EO; Brandenburg Medical School, Institute of Laboratory Medicine, Brandenburg Hospital, Brandenburg, Germany.; Faculty of Medicine, Institute of Medical Microbiology and Hygiene, Medical Center-University of Freiburg, Freiburg, Germany.
Jazyk: angličtina
Zdroj: Helicobacter [Helicobacter] 2021 Feb; Vol. 26 (1), pp. e12765. Date of Electronic Publication: 2020 Oct 17.
DOI: 10.1111/hel.12765
Abstrakt: Background: Antimicrobial therapy is recommended to eradicate Helicobacter (H.) pylori in infected individuals. As first-line treatments are empiric, knowledge of antimicrobial resistance is key to successful eradication.
Aims: We investigated primary resistance in an eastern German region to derive recommendations for eradication treatment.
Methods: We used molecular genetic methods to examine Helicobacter rapid urease test (RUT) positive gastric specimens of 533 patients from Berlin and the federal state of Brandenburg with allegedly no prior eradication treatment. Tissue samples were removed from RUT and screened by real-time PCR for mutations conferring resistance to clarithromycin. In addition, 182 samples out of 533 were tested for resistance to levofloxacin and tetracycline.
Results: Primary resistances were 10.9% (58 out of 533) to clarithromycin; 13.7% (25/182) to levofloxacin; and 2.2% to tetracycline (4/182). Combined resistance to clarithromycin/levofloxacin was low (2.2%, 4/182). Female sex was significantly associated with clarithromycin resistance.
Conclusion: Clarithromycin may be a suitable first-line antibiotic for about 90% of outpatients. A simple molecular test may help physicians avoid prescription of an ineffective first-line regimen.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje